Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Total Assets by Geographic Area


			December 31,
			2025				2024
	Long-lived Assets
	Chinese Mainland		$	766,684			$	945,359
	Outside Chinese Mainland			11,982				13,158
	Total Long-lived Assets		$	778,666			$	958,517

Schedule of Revenues are Attributed to Geographic Locations

The Company's revenues are attributed to geographic locations as follows:


			For the year ended December 31,
			2025				2024				2023
	Sales
	Chinese Mainland		$	261,184			$	297,003			$	402,957
	Outside Chinese Mainland			124,829				64,371				67,213
	Total Sales		$	386,013			$	361,374			$	470,170

Summarizes of Significant Expenses

The table below summarizes the significant expense categories regularly reviewed by the CODM:


			For the year ended December 31,
			2025				2024				2023
	Sales		$	386,013			$	361,374			$	470,170
	Cost of sales			124,032				140,688				146,853
	Research and development expenses:
	Pneumococcal Conjugate Vaccine			38,859				43,228				44,121
	Bivalent Enterovirus Vaccine			19,995				13,722				6,659
	Pentavalent DTaP-IPV/Hib Combination Vaccine			17,325				33,767				93,211
	Rabies vaccine for human use			15,507				45,641				28,365
	Group ACYW135 Meningococcal Conjugate Vaccine			13,522				21,647				29,174
	Adsorbed Tetanus Vaccine			11,772				7,725				1,365
	Others (a)			99,200				104,931				147,292
	Selling, general and administrative expenses			332,979				420,922				598,250
	Other segment income (expense) (b)			88,342				511,553				504,262
	Net (loss) income		$	(198,836	)		$	40,656			$	(120,858	)

(a) Includes research and development expenses on other product candidates at preliminary stage.

(b) Other segment income (expense) includes provision for credit losses, loss on disposal and impairment of property, plant and equipment, loss on impairment of intangible assets, loss on impairment of goodwill, government grants recognized in income, interest and financing expenses, interest income, share of losses from equity method investments, income tax benefit (expense), and other income, net.